Atlas Trials

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC

Clinical trial NCT05189730 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05189730
Sponsor
Sichuan Cancer Hospital and Research Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2021-07-01
Primary completion
2025-01-31
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.